NCT05173246View on ClinicalTrials.gov

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Esophageal Small Cell Carcinoma
Interventions
DRUG

JS001

JS001 240mg, ivdrip, d1, Q3w

DRUG

nab-paclitaxel

nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w

DRUG

Cisplatin

Cisplatin 75mg/m2, ivdrip,d1,Q3w

DRUG

Carboplatin

Carboplatin AUC 5,d1,Q3w

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Sun Yat-sen University

OTHER